Most cited papers from Fundación Huésped

Fundación Huésped

What are the most cited papers from Fundación Huésped?

The most cited paper from Fundación Huésped is "Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women" (Raphael J. Landovitz et al., 2021), with 913 citations. Next come "False-negative results of initial RT-PCR assays for COVID-19: A systematic review" (697) and "Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study" (686).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 59 papers. Every paper with more than 81 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women Raphael J. Landovitz et al. · New England Journal of Medicine Open access	11 Aug 2021	913
2	False-negative results of initial RT-PCR assays for COVID-19: A systematic review Ingrid Arévalo-Rodríguez, Diana Buitrago‐García, Daniel Simancas‐Racines et al. · PLoS ONE ReviewOpen access	10 Dec 2020	697
3	Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study Frank van Leth et al. · The Lancet	Apr 2004	686
4	Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression Susan Swindells et al. · New England Journal of Medicine Open access	4 Mar 2020	600
5	Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study Pedro Enrique Cahn et al. · The Lancet Open access	3 Jul 2013	518
6	Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial José Valdez Madruga, Pedro Enrique Cahn, Beatriz Gilda Jegerhorn Grinsztejn et al. · The Lancet	Jul 2007	517
7	Antiretroviral Treatment of Adult HIV Infection Huldrych Fritz Günthard, Judith A. Aberg, Joseph J. Eron et al. · JAMA	19 Jul 2014	453
8	Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial Jean‐Michel Molina, Pedro Enrique Cahn, Beatriz Gilda Jegerhorn Grinsztejn et al. · The Lancet	Jul 2011	404
9	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials Pedro Enrique Cahn et al. · The Lancet Open access209 authors	9 Nov 2018	391
10	Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials Charles B. Hicks, Pedro Enrique Cahn, David A. Cooper et al. · The Lancet	Aug 2006	324
11	Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration Rami Kantor et al. · PLoS Medicine Open access	19 Apr 2005	319
12	International Anal Neoplasia Society's consensus guidelines for anal cancer screening Elizabeth A. Stier, Megan A. Clarke, Ashish Ambadas Deshmukh et al. · International Journal of Cancer Open access	31 Jan 2024	306
13	Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons Colleen Frances Kelley et al. · New England Journal of Medicine	27 Nov 2024	285
14	Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1 Frank van Leth, Prahpan Phanuphak, Erik S.G. Stroes et al. · PLoS Medicine Open access	7 Oct 2004	276
15	Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial Scott A. Halperin et al. · The Lancet Open access	23 Dec 2021	238
16	Overview of SARS-CoV-2 infection in adults living with HIV Juan Ambrosioni et al. · The Lancet HIV Open access	27 Apr 2021	225
17	Universal Definition of Loss to Follow-Up in HIV Treatment Programs: A Statistical Analysis of 111 Facilities in Africa, Asia, and Latin America Benjamin H. Chi, Constantin Theodore Yiannoutsos, Andrew O. Westfall et al. · PLoS Medicine Open access	25 Oct 2011	225
18	Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials Pedro Enrique Cahn et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes Open access	12 Dec 2019	216
19	Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Edward J. Mills, William A. Schabas, Jimmy A Volmink et al. · The Lancet Open access	Feb 2008	207
20	Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects Robert L Murphy, Ian Sanne, Pedro Enrique Cahn et al. · AIDS	13 Nov 2003	194
21	Factors associated with healthcare avoidance among transgender women in Argentina M. Eugenia Socías, Brandon D. L. Marshall, Inés Arístegui et al. · International Journal for Equity in Health Open access	26 Sep 2014	194
22	Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection Michael Kozal, Judith A. Aberg, Gilles Pialoux et al. · New England Journal of Medicine Open access	25 Mar 2020	184
23	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV Jeffrey Victor Lazarus et al. · Nature Communications Open access	16 Jul 2021	163
24	Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients Calvin J. Cohen, Jean‐Michel Molina, Pedro Enrique Cahn et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	17 Feb 2012	158
25	Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial Pedro Enrique Cahn, Jaime Federico Andrade-Villanueva, José Ramón Arribas et al. · The Lancet Infectious Diseases	27 Apr 2014	158
26	Causes of Blindness and Visual Impairment in Latin America João M. Furtado, Van Charles Lansingh, Marissa Janine Carter et al. · Survey of Ophthalmology	7 Dec 2011	152
27	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial Jean‐Michel Molina et al. · The Lancet HIV 140 authors	25 Mar 2018	150
28	Improved Diagnosis of Strongyloides stercoralis Using Recombinant Antigen-Based Serologies in a Community-Wide Study in Northern Argentina Alejandro Javier Krolewiecki, Roshan Ramanathan, Valeria Fink et al. · Clinical and Vaccine Immunology Open access	26 Aug 2010	150
29	Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme Catherine C. McGowan, Pedro Enrique Cahn, Eduardo Gotuzzo et al. · International Journal of Epidemiology Open access	10 Sep 2007	145
30	Clinical and public health implications of acute and early HIV detection and treatment: a scoping review Sarah E. Rutstein, Jintanat Ananworanich, Sarah J. Fidler et al. · Journal of the International AIDS Society Open access	2017	143
31	Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children Xavier Sáez‐Llorens, AVYI VIOLARI, Carl O. Deetz et al. · The Pediatric Infectious Disease Journal	Mar 2003	142
32	Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection Pedro Cahn et al. · AIDS Open access	15 Sep 2021	137
33	A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study) Daniel Podzamczer et al. · Antiviral Therapy	Feb 2002	137
34	ISRIA statement: ten-point guidelines for an effective process of research impact assessment Paula Adam, Pavel V. Ovseiko, Jonathan Grant et al. · Health Research Policy and Systems Open access	8 Feb 2018	127
35	A global call for action to include gender in research impact assessment Pavel V. Ovseiko et al. · Health Research Policy and Systems Open access	18 Jul 2016	124
36	Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis Melisa Dirchwolf · World Journal of Hepatology Open access	2015	121
37	Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults Graeme J Moyle, Edwin DeJesus, Pedro Enrique Cahn et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	Mar 2005	119
38	Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Trial Ulrik Bak Dragsted, Jan Gerstoft, Court Pedersen et al. · The Journal of Infectious Diseases Open access	22 Aug 2003	118
39	Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients Pedro Enrique Cahn, Jan Fourie, Beatriz Gilda Jegerhorn Grinsztejn et al. · AIDS	23 Feb 2011	115
40	Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial Kelly E. Dooley et al. · Clinical Infectious Diseases Open access	25 Mar 2019	113
41	Expert consensus statement on the science of HIV in the context of criminal law Françoise Barré‐Sinoussi, Salim S. Abdool Karim, Jan Albert et al. · Journal of the International AIDS Society Open access	Jul 2018	113
42	Induction of HIF-1α by HIV-1 Infection in CD4 + T Cells Promotes Viral Replication and Drives Extracellular Vesicle-Mediated Inflammation Gabriel Duette, Pehuén Pereyra Gerber, Julia Rubione et al. · mBio Open access	10 Sep 2018	112
43	Long-Term Efficacy and Safety of Atazanavir With Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or Atazanavir Robin Wood, Praphan Phanuphak, Pedro Enrique Cahn et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes	17 May 2004	103
44	Dolutegravir–lamivudine as initial therapy in HIV‐1 infected, ARV‐naive patients, 48‐week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study Pedro Enrique Cahn, María José Rolón, María Inés Figueroa et al. · Journal of the International AIDS Society Open access	2017	102
45	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial Jean‐Michel Molina et al. · The Lancet HIV 143 authors	15 Nov 2019	101
46	Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis Sandra A. Mathis, Bettina Khanlari, Federico Pulido et al. · PLoS ONE ReviewOpen access	19 Jul 2011	101
47	Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial Margaret Johnson, Princy N. Kumar, Jean‐Michel Molina et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes Open access	15 Apr 2019	100
48	Comprehensive analysis of unique cases with extraordinary control over HIV replication Daniel Mendoza et al. · Blood Open access	6 Apr 2012	95
49	Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study Max Lataillade et al. · The Lancet HIV	28 Oct 2020	94
50	Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis Amitabh Bipin Suthar, Marco Vitória, Jason M. Nagata et al. · The Lancet HIV Review	2 Mar 2015	94

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.